Is There a Place for Bone Turnover Markers in the Assessment of Osteoporosis and its Treatment?

被引：31

作者：

Devogelaer, Jean-Pierre ^{[1
,2
]}

Boutsen, Yves ^{[3
,4
]}

Gruson, Damien ^{[5
,6
]}

Manicourt, Daniel ^{[1
,2
]}

机构：

[1] Catholic Univ Louvain, St Luc Univ Hosp, Div Rheumatol, B-1200 Brussels, Belgium

[2] Catholic Univ Louvain, St Luc Univ Hosp, Rheumatol Unit, Dept Med,UCL 5390, B-1200 Brussels, Belgium

[3] Univ Catholique Louvain Brussels, St Luc Univ Hosp, Div Rheumatol, Dept Med,UCL 5390, B-5530 Yvoir, Belgium

[4] Univ Hosp Mt Godinne, B-5530 Yvoir, Belgium

[5] Catholic Univ Louvain, St Luc Univ Hosp, Dept Lab Med, B-1200 Brussels, Belgium

[6] Catholic Univ Louvain, St Luc Univ Hosp, Dept Clin Biochem, B-1200 Brussels, Belgium

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2011年 / 37卷 / 03期

关键词：

Osteoporosis; Therapy; Biologic markers; Bone remodeling; Bisphosphonates; Promotors of bone formation; VERTEBRAL FRACTURE RISK; YEARLY ZOLEDRONIC ACID; PREDICTS HIP FRACTURE; BIOCHEMICAL MARKERS; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; ELDERLY-WOMEN; RISEDRONATE TREATMENT; PARATHYROID-HORMONE; STRONTIUM RANELATE;

D O I：

10.1016/j.rdc.2011.07.002

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

As populations age, the number of osteoporotic fractures will increase. Bone mineral density (BMD) measurement remains the major way to diagnose osteoporosis and to indicate therapy. The FRAX tool, based on clinical risk factors, estimates the 10-year risk of hip and major osteoporotic fractures. The association of BMD and FRAX measurements has improved the identification of patients who are most at risk. However, some patients can still be overlooked and denied therapy. It is sound that adding the measure of bone turnover markers to the former risk factors and their follow-up during therapy could best address the efficacy of treatment of osteoporosis. Whether this behavior is cost-effective remains to be settled.

引用

页码：365 / +

页数：24

共 81 条

[1]

Bone density and markers of bone remodeling in type 1 male diabetic patients [J].

Alexopoulou, O. ;

Jamart, J. ;

Devogelaer, J. P. ;

Brichard, S. ;

de Nayer, P. ;

Buysschaert, M. .

DIABETES & METABOLISM, 2006, 32 (05) :453-458

[2]

[Anonymous], 1994, WHO TECHN REP SER, V843

[3]

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].

Bauer, DC ;

Black, DM ;

Garnero, P ;

Hochberg, M ;

Ott, S ;

Orloff, J ;

Thompson, DE ;

Ewing, SK ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258

[4]

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial [J].

Bauer, DC ;

Garnero, P ;

Hochberg, MC ;

Santora, A ;

Delmas, P ;

Ewing, SK ;

Black, DM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) :292-299

[5]

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club [J].

Bergmann, P. ;

Body, J. -J. ;

Boonen, S. ;

Boutsen, Y. ;

Devogelaer, J. -P. ;

Goemaere, S. ;

Kaufman, J. -M. ;

Reginster, J. -Y. ;

Gangji, V. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) :19-26

[6]

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].

Bjarnason, NH ;

Sarkar, S ;

Duong, T ;

Mitlak, B ;

Delmas, PD ;

Christiansen, C .

OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930

[7]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[8]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[9]

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[10]

Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

← 1 2 3 4 5 6 7 8 9 →